| Offering Information |
| Expected Date | WITHDRAWN |
| Proposed Exchange/Ticker |
Nasdaq: APBI |
| Security Type |
Common Stock |
| Lead Underwriter |
Morgan Stanley Dean Witter |
| Days In Registration |
568 |
| Date Filed |
2-Oct-2000 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2012) |
| Industry |
Pers/Bus/Rep Svc |
| Business Description |
Provides biotechnology systems, products and services for research into genes and proteins, for the discovery and development of drugs, and for the manufacture of biopharmaceuticals; provides researchers with reagents, equipment and software |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
208.63M |
| CEO |
Andrew Carr |
| Number of Employees |
4300 |
|
| Original Filing Information |
| US |
| Shares Filed |
18.2M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
- |
| · As a Percent |
- |
| Overallotment Shares Filed |
2730.0K |
| File Amount |
- |
| File Price Range |
$17.00 - $15.00 |
| File Mid Price |
$16.00 |
|
